Whitehawk Therapeutics awarded Chief Scientific Officer Dornan David 171,774 derivative securities in two code A transactions on September 15 at $0 per share. After the transactions, David owned 85,887 derivative securities, giving investors the reported post-transaction holding tied to the company’s disclosed award activity.
Key Highlights
- The transactions were recorded on 15 September 2026 at $0 per share.
- Dornan David owned 85,887 derivative securities after the transactions.
- The transactions carried SEC transaction code A.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded 171,774 derivative securities across two transactions. Dornan David, the company’s chief scientific officer, received the awards.
The transactions carried SEC transaction code A. They were recorded on 15 September 2026 at $0 per share. The awards covered derivative securities of Whitehawk Therapeutics.
Reported Post-Transaction Position
Following the transactions, Dornan David owned 85,887 derivative securities. That figure represents the reported holding after the award activity. Whitehawk Therapeutics identified David as its chief scientific officer. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: How many derivative securities did Dornan David receive from Whitehawk Therapeutics?
A: Whitehawk Therapeutics awarded Dornan David 171,774 derivative securities in two separate transactions filed under SEC transaction code A. The transactions occurred on 15 September 2026.
Q: What price did Whitehawk Therapeutics set for Dornan David’s derivative securities?
A: The transactions were recorded at $0 per share on 15 September 2026. The filing identifies Dornan David as Whitehawk Therapeutics’ chief scientific officer.
Q: How many derivative securities did Dornan David own afterward?
A: Following the two transactions, Dornan David owned 85,887 derivative securities of Whitehawk Therapeutics. This was the post-transaction holding reported in the filing.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.